Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

6.160 -0.130 (-2.07%)
Streaming Delayed Price Updated: 2:31 PM EDT, Apr 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Candel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
From Candel Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
From Candel Therapeutics
Via GlobeNewswire
News headline image
Recap: Candel Therapeutics Q4 Earnings ↗
 
Via Benzinga
Candel Therapeutics Sets Stage For Success With Cancer-Fighting Immunotherapies
--News Direct-- 
Via News Direct
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
What's Going On With Candel Therapeutics Stock On Friday? ↗
Candel Therapeutics sees surge in shares amid robust volume, buoyed by promising interim data from CAN-2409 phase 2 trial for non-metastatic prostate cancer. Exciting developments continue with updated... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Unusually High Volume Points to Upside in These Stocks
Unusually high volume is often a signal of higher price to come; this is a look at three stocks with recent volume spikes and a reason for the price to advance. 
Via MarketBeat
Topics ETFs
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
It's time to dive into all of the biggest pre-market stock movers that traders will want to keep an eye on Friday morning! 
Via InvestorPlace
News headline image
Ford, Candel Therapeutics, Nvidia, Palantir, Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results ↗
U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday. The Dow traded down 0.59% to 38,894.58 while the NASDAQ fell 0.10% to 16,261.88.... 
Via Benzinga
Topics Stocks
News headline image
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3%... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings ↗
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow traded up 0.49% to 39,319.03 while the NASDAQ rose 1% to 16,4340. The S&P... 
Via Benzinga
Topics Stocks
News headline image
After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study ↗
Candel Therapeutics updates phase 2 trial results for CAN-2409 and valacyclovir in pancreatic cancer treatment, revealing prolonged survival rates up to 28.8 months versus standard therapy's 12.5... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
From Candel Therapeutics
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
We're diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Thursday morning! 
Via InvestorPlace
News headline image
Micro-Cap Cancer Focused Candel Therapeutics Highlights Encouraging Data From Brain Tumor Immunotherapy ↗
Data from Candel Therapeutics on CAN-3110, a promising viral immunotherapy for recurrent high-grade glioma. Discover survival rates and potential advancements in cancer treatment. 
Via Benzinga
News headline image
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
From Candel Therapeutics
Via GlobeNewswire
News headline image
CADL Stock Earnings: Candel Therapeutics Misses EPS for Q4 2023 ↗
CADL stock results show that Candel Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors
--News Direct-- 
Via News Direct
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
From Candel Therapeutics
Via GlobeNewswire
Moving Fast: Candel’s (NASDAQ: CADL) CAN-3110 Granted FDA Fast Track Designation For Recurrent High-Grade Glioma Following Fast Track Designation For CAN-2409 In Pancreatic Cancer
--News Direct-- 
Via News Direct
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Candel Therapeutics Sets Stage For Success With Cancer-Fighting Immunotherapies ↗
A clinical-stage biopharmaceutical company looks forward to the year ahead with several promising developments in motion.  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.